Tags

Type your tag names separated by a space and hit enter

Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial.
Indian Pediatr. 2019 06 15; 56(6):468-471.IP

Abstract

OBJECTIVE

To evaluate the efficacy of ondansetron for the treatment of vomiting and thus reducing the need for intravenous (IV) rehydration in children with gastroenteritis.

DESIGN

Double-blind, placebo-controlled, randomized trial.

SETTING

Pediatric ward of An Giang General Hospital, South Vietnam, between December 2013 and June 2014.

PARTICIPANTS

61 inpatient children (age 11-60 mo) suffering from gastroenteritis with vomiting. Exclusion criteria were: underlying chronic conditions, immunodeficiency, malnutrition or history of allergy to ondansetron.

INTERVENTION

Single bolus of IV ondansetron at a dose of 0.2 mg/kg or placebo.

OUTCOME MEASURES

Proportion of patients who needed IV rehydration, proportion of patients with cessation of vomiting, amount of oral rehydration solution intake, duration of diarrhea and the length of hospital stay.

RESULTS

After drug administration, 22 (73%) of the 30 patients in the ondansetron group had complete cessation of vomiting compared with 7 (23%) of the 31 patients in the placebo group (RR 0.32; 95% CI 0.16 to 0.63, P<0.001). 3 (10%) patients in the ondansetron group required IV rehydration as compared with 12 (39%) in the placebo group (RR 0.51; 95% CI 0.33 to 0.79, P=0.009). The median amount of oral rehydration solution intake in 24 hours was significantly greater in the ondansetron group (450 mL vs 350 mL, P=0.019).The duration of diarrhea and the length of hospital stay were not different between the two groups.

CONCLUSIONS

In hospitalized children having gastro-enteritis associated with emesis, ondansetron is effective in the cessation of episodes of vomiting and in lowering the rates of IV rehydration, without reducing the duration of diarrhea and hospital stay.

Authors+Show Affiliations

Department of Pediatrics, Can Tho University of Medicine and Pharmacy, Vietnam. Correspondence to: Dr Nguyen Ngoc Rang, Pediatric Department of Can Tho University of Medicine and Pharmacy, 179 Nguyen Van Cu, Can Tho, Vietnam. nguyenngocrang@gmail.com.Department of Pediatrics, An Giang Hospital, Vietnam.Department of Pediatrics, An Giang Hospital, Vietnam.Department of Pediatrics, An Giang Hospital, Vietnam.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

31278225

Citation

Rang, Nguyen Ngoc, et al. "Single-dose Intravenous Ondansetron in Children With Gastroenteritis: a Randomized Controlled Trial." Indian Pediatrics, vol. 56, no. 6, 2019, pp. 468-471.
Rang NN, Chanh TQ, My PT, et al. Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial. Indian Pediatr. 2019;56(6):468-471.
Rang, N. N., Chanh, T. Q., My, P. T., & Tien, T. T. M. (2019). Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial. Indian Pediatrics, 56(6), 468-471.
Rang NN, et al. Single-dose Intravenous Ondansetron in Children With Gastroenteritis: a Randomized Controlled Trial. Indian Pediatr. 2019 06 15;56(6):468-471. PubMed PMID: 31278225.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Single-dose Intravenous Ondansetron in Children with Gastroenteritis: A Randomized Controlled Trial. AU - Rang,Nguyen Ngoc, AU - Chanh,Ton Quang, AU - My,Pham The, AU - Tien,Truong Thi My, PY - 2019/7/7/entrez PY - 2019/7/7/pubmed PY - 2020/2/6/medline SP - 468 EP - 471 JF - Indian pediatrics JO - Indian Pediatr VL - 56 IS - 6 N2 - OBJECTIVE: To evaluate the efficacy of ondansetron for the treatment of vomiting and thus reducing the need for intravenous (IV) rehydration in children with gastroenteritis. DESIGN: Double-blind, placebo-controlled, randomized trial. SETTING: Pediatric ward of An Giang General Hospital, South Vietnam, between December 2013 and June 2014. PARTICIPANTS: 61 inpatient children (age 11-60 mo) suffering from gastroenteritis with vomiting. Exclusion criteria were: underlying chronic conditions, immunodeficiency, malnutrition or history of allergy to ondansetron. INTERVENTION: Single bolus of IV ondansetron at a dose of 0.2 mg/kg or placebo. OUTCOME MEASURES: Proportion of patients who needed IV rehydration, proportion of patients with cessation of vomiting, amount of oral rehydration solution intake, duration of diarrhea and the length of hospital stay. RESULTS: After drug administration, 22 (73%) of the 30 patients in the ondansetron group had complete cessation of vomiting compared with 7 (23%) of the 31 patients in the placebo group (RR 0.32; 95% CI 0.16 to 0.63, P<0.001). 3 (10%) patients in the ondansetron group required IV rehydration as compared with 12 (39%) in the placebo group (RR 0.51; 95% CI 0.33 to 0.79, P=0.009). The median amount of oral rehydration solution intake in 24 hours was significantly greater in the ondansetron group (450 mL vs 350 mL, P=0.019).The duration of diarrhea and the length of hospital stay were not different between the two groups. CONCLUSIONS: In hospitalized children having gastro-enteritis associated with emesis, ondansetron is effective in the cessation of episodes of vomiting and in lowering the rates of IV rehydration, without reducing the duration of diarrhea and hospital stay. SN - 0974-7559 UR - https://www.unboundmedicine.com/medline/citation/31278225/Single_dose_Intravenous_Ondansetron_in_Children_with_Gastroenteritis:_A_Randomized_Controlled_Trial_ L2 - https://www.indianpediatrics.net/june2019/468.pdf DB - PRIME DP - Unbound Medicine ER -